Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Maggie, Beck, Evan J., Laeyendecker, Oliver, Eby, Yolanda, Tobian, Aaron A. R., Caturegli, Patrizio, Wouters, Camille, Chiklis, Gregory R., Block, William, McKie, Robert O., Joyner, Michael J., Wiltshire, Timothy D., Dietz, Allan B., Gniadek, Thomas J., Shapiro, Arell J., Yarava, Anusha, Lane, Karen, Hanley, Daniel F., Bloch, Evan M., Shoham, Shmuel, Cachay, Edward R., Meisenberg, Barry R., Huaman, Moises A., Fukuta, Yuriko, Patel, Bela, Heath, Sonya L., Levine, Adam C., Paxton, James H., Anjan, Shweta, Gerber, Jonathan M., Gebo, Kelly A., Casadevall, Arturo, Pekosz, Andrew, Sullivan, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023079/
https://www.ncbi.nlm.nih.gov/pubmed/35443020
http://dx.doi.org/10.1182/bloodadvances.2022007410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023079/
https://www.ncbi.nlm.nih.gov/pubmed/35443020
http://dx.doi.org/10.1182/bloodadvances.2022007410

Ejemplares similares